
ALLERGIKA Pharma Germany business opportunities in dust mite allergy treatment with ALLERGIKA® Encasings medical device





- Dust mite allergy is a very common disease
- 15% of the population suffer from dust mite allergy
- A fast growing market of 10% new cases yearly
- ALLERGIKA® Encasings: new generation of medical device
- ALLERGIKA® Encasings: No 1 in the German market

ALLERGIKA® Encasings No. 1 in Germany

- ALLERGIKA® Encasings reduce symptoms of allergic diseases
 - bronchial asthma
 - atopic dermatitis
 - eczema
 - allergic rhinitis
 - conjunctivitis
- ALLERGIKA® Encasings prevent from dust mite allergens in bed
 - 75% of house dust mites are living in mattress, pillow and blanket
- ALLERGIKA® Encasings are a mechanical barrier between human and allergens
 - without cortisone
 - high clinical efficacy
 - immediate reduction of symptoms

ALLERGIKA® Encasings

are recommended by specialists as basic treatment according to International Guidelines.







ALLERGIKA® Encasings clinical prooven efficacy

- 1 ALLERGIKA® Encasings are medical device class 1
 - registered in EU
- 2 ALLERGIKA® Encasings: new generation of medical textile
 - best certificates
- 3 ALLERGIKA® Encasings: 99% allergen retention
 - symptoms will be reduced immediately proven effective by TÜV Germany
- 4 ALLERGIKA® Encasings offer best sleeping comfort
 - very high air and steam permeability
- 5 ALLERGIKA® Encasings: ÖKO Tex approved
 - suitable for babies from day one
- 6 ALLERGIKA® Encasings are evidence based
 - in line with all International Guidelines
- 7 ALLERGIKA® Encasings are medical special covers for
 - medical special textiles for covering
 - mattress
 - pillow
 - blanket
 - available in more than 300 sizes















Dust mite allergy

General information

Allergen exposure in the home significantly influences the frequently and serverity of various allergic symptoms. Among other factors, dust mites and their excrements are one of the dominant allergens that cause asthma, atopic dermatitis or allergic rhinitis. According to a statistic of the WHO 15% of the European population suffer from dust mite allergies and the numbers are rising. ALLERGIKA®Encasings are a safe and effective therapeutic option to reduce allergic symptoms.

Ranking	Indication	Number of patients	Percentage
1	Dry, sensitive and irritating skin	350 million	50%
2	Sun allergy	140 million	20%
3	Dust mite allergy	120 million	15%
4	Pollen	120 million	17%
5	Allergic asthma	100 million	14%
6	Contact dermatitis	80 million	11%
7	Atopic dermatitis	25 million	4%
8	Sensitive skin of babies and kids	8 million	1%



ALLERGIKA® Pharma GmbH offers:

- → Long-term distribution agreement
- → Exclusivity
- → Interesting margins

Please get in touch with us: ALLERGIKA Pharma GmbH 82515 Wolfratshausen, Germany Phone: +49 8171 – 4225-840 Email: international@allergika.de

www.allergika.de